🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchOrforglipron ATTAIN-4 — my results so far Page 9

Orforglipron ATTAIN-4 — my results so far

roxy_nash Sat, Jul 12, 2025 at 6:46 AM 43 replies 2,076 viewsPage 9 of 9
KevinCompounds
VIP Member
5,432
18,234
Dec 2023
Nevada
Feb 14, 2026 at 6:35 AM#41
stefan_berlin said:
Worth stating the units and the reference range whenever you post a number here.

Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.

2 0jennifer_SEA, tyler_CSCS
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Feb 24, 2026 at 2:10 AM#42

Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

3 1alex_tucson, kevin_tulsa, Dr.PainCLE
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Mar 5, 2026 at 9:51 PM#43

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.

4 2RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 1 other
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Mar 15, 2026 at 5:38 PM#44
PharmHunterJen said:
The mechanism and the magnitude are separate questions.

Coming at PharmHunterJen’s question from a different direction. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Last edited: Mar 15, 2026 at 6:38 PM
5 3NicoleRaleigh, james_edin, FranDenver and 2 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Mar 25, 2026 at 1:30 PM#45

Adding the numbers, since they settle part of this. If you are comparing against somebody else’s result, check that you are comparing the same measurement taken the same way. Most of the apparent contradictions in these threads dissolve at that step.

6 4RickReta_CO, PharmHunterJen, TomTeleRx and 3 others
Reply Quote Save Share Report
1789

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register